Active, not recruitingPHASE2, PHASE3NCT05707377
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
Studying Primary membranous glomerulonephritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BeOne Medicines
- Principal Investigator
- Study DirectorBeOne Medicines
- Intervention
- Zanubrutinib(drug)
- Enrollment
- 178 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2023 – 2027
Study locations (30)
- Amicis Research Center, Northridge, California, United States
- Stanford University, Palo Alto, California, United States
- Intermed Consultants, Minneapolis, Minnesota, United States
- Kidney Specialist of Southern Nevada (Ksosn), Las Vegas, Nevada, United States
- University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
- Carolina Nephrology, Spartanburg, South Carolina, United States
- Instituto Pro Renal Brasil, Curitiba, Brazil
- Hcfmusp Hospital Das Clinicas Da Faculdade de Medicina Da Universidade de Sao Paulo, São Paulo, Brazil
- Ott Healthcare, Inc (Corporate Medical Centre), Scarborough Village, Ontario, Canada
- Beijing An Zhen Hospital, Capital Medical University, Beijing, Beijing Municipality, China
- Peking University First Hospital, Beijing, Beijing Municipality, China
- Fujian Medical University Union Hospital, Fuzhou, Fujian, China
- The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
- The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
- Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05707377 on ClinicalTrials.govOther trials for Primary membranous glomerulonephritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07289763Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous NephropathyGuangdong Hengrui Pharmaceutical Co., Ltd
- RECRUITINGPHASE2, PHASE3NCT07204275A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)Vertex Pharmaceuticals Incorporated
- RECRUITINGPHASE2NCT07157787Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)Alexion Pharmaceuticals, Inc.
- RECRUITINGPHASE2NCT07096843A Phase 2 Study of Budoprutug in Subjects With Primary Membranous NephropathyClimb Bio, Inc.
- RECRUITINGPHASE3NCT06962800A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)Biogen
- RECRUITINGPHASE1NCT06982729Study of YK012 in Primary Membranous NephropathyExcyte Biopharma Ltd
- RECRUITINGNCT06242327An Outcome Analysis of Primary Membranous NephropathyMario Negri Institute for Pharmacological Research
- ACTIVE NOT RECRUITINGPHASE2NCT06642909A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous NephropathyBioRay Pharmaceutical Co., Ltd.